



## Exploring a path that may delay the development of Parkinson's Disease symptoms

Researchers from the University of Calgary need your help!

You may be eligible to participate if you are **between 30-80 years old, Parkinson's disease diagnosed within the last 2 years and never treated with Parkinson's medications\***.

\*The study team will discuss with you the additional criteria required to participate.

The Luma study is evaluating the safety and efficacy of a study drug, as compared to a placebo, to see if it may delay the progression of Parkinson's in its early stages. The study drug is thought to lower the activity of a protein in your body that may play a role in symptoms of Parkinson's disease.

- The LUMA Study lasts a minimum of 1 year and up to 3 years.
- The study includes up to 20 study visits.
- All study-related care, genetic testing, and the study drug at no charge (the study drug, or the placebo, is a tablet taken by mouth once daily).
- Regular monitoring of your Parkinson's disease and overall health by physicians who specialize in Parkinson's disease.
- The opportunity to contribute to learning more about Parkinson's disease.

The study visits will happen at the Cumming School of Medicine. We will reimburse you for transportation and rideshare to attend study visits, as needed.

**If you have additional questions and are interested in being part of this clinical trial study:**

Please contact our research coordinator, **Carolina De la Rosa** by email [carolina.delarosa1@ucalgary.ca](mailto:carolina.delarosa1@ucalgary.ca)

**Principal Investigator: Dr. Camila Aquino**

Useful websites: [https://www.parkinsonsresearchstudies.com/?utm\\_source=parkinsonsfoundation&utm\\_medium=vanity&utm\\_campaign=luminare&utm\\_term=url&utm\\_content=luminarepdstudiesdotcom](https://www.parkinsonsresearchstudies.com/?utm_source=parkinsonsfoundation&utm_medium=vanity&utm_campaign=luminare&utm_term=url&utm_content=luminarepdstudiesdotcom)



This study has been approved by the University of Calgary Conjoint Health Research Ethics Board Ethics ID# REB 22-0363



DEPARTMENT OF CLINICAL NEUROSCIENCES

A partnership between Alberta Health Services and the Cumming School of Medicine



UNIVERSITY OF CALGARY